Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 10/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.65 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.63 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22245273 | 1.00 | GCGR (0.76) | GCGRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL14983781 | 0.87 | AR (0.76) | GCGRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL1639477 | 0.84 | RRM1 (0.77) | GCGRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL12766750 | 0.84 | RRM1 (0.77) | GCGRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL1639479 | 0.84 | RRM1 (0.77) | GCGRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL6568237 | 0.82 | KMT2A (0.77) | GCGRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL6568234 | 0.82 | KMT2A (0.77) | GCGRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2663817 | 0.82 | GCGR (1.00) | GCGRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL28515981 | 0.81 | NTRK1 (0.81) | GCGRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL23327368 | 0.80 | GCGR (0.72) | GCGRMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10722489-B2 | D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof | PEKING UNIVERSITY (CN) | 2020-07-28 | — | — | US | disclosed |
| US-20200054593-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | UNIV BEIJING (CN) | 2020-02-20 | — | — | US | disclosed |
| US-20200054593-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | UNIV BEIJING (CN) | 2020-02-20 | — | — | US | disclosed |
| US-20190262303-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | UNIV BEIJING (CN) | 2019-08-29 | — | — | US | disclosed |
| WO-2018076537-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | 北京大学 | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10722489-B2 | D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof | MDH2, MDH1, DLD | GCGR 2751/4885MEN1 2502/4885KMT2A 1899/4885 |
| US-20200054593-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | MDH2, MDH1, DLD | GCGR 2751/4885MEN1 2502/4885KMT2A 1899/4885 |
| US-20190262303-A1 | D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF | MDH2, MDH1, DLD | GCGR 2751/4885MEN1 2502/4885KMT2A 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.